Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CalciMedica, Inc.CALC · Entity 7804 | Director · CHIEF BUSINESS OFFICER | August 19, 2026 | August 21, 2026 |
| VIVUS INCVVUS · Entity 151460 | Director | February 28, 2019 | March 04, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CalciMedica, Inc.
Report date August 19, 2026 · Filed August 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $0.80 · Expires 2027-12-25 | Direct | 186,729 |
Reported balance
After 2026-08-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-19 · Grant · Acquired 186,729 · Balance 186,729 F1: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. F2: The warrant may be exercised on or after August 19, 2026, and on or prior to the earlier of (i) December 25, 2027 and (ii) thirty (30) days following the Issuer's public disclosure of the clearance of its Investigational New Drug Application by the U.S. Food and Drug Administration for CM5480; provided, however, that the holder will be prohibited, subject to certain exceptions, from exercising such warrant for shares of common stock of the Issuer to the extent that immediately prior to or after giving effect to such exercise, the holder, together with its affiliates and other attribution parties, would own more than 19.99% of the total number of shares of common stock of the Issuer then issued and outstanding, which percentage may be changed at the holder's election to a lower percentage at any time or to a higher percentage upon 61 days' notice to the Issuer. |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $1.00 · Expires 2031-06-25 | Direct | 186,729 |
Reported balance
After 2026-08-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-19 · Grant · Acquired 186,729 · Balance 186,729 F1: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. F3: The warrant may be exercised on or after August 19, 2026 and on or prior to June 25, 2031; provided, however, that the holder will be prohibited, subject to certain exceptions, from exercising such warrant for shares of common stock of the Issuer to the extent that immediately prior to or after giving effect to such exercise, the holder, together with its affiliates and other attribution parties, would own more than 19.99% of the total number of shares of common stock of the Issuer then issued and outstanding, which percentage may be changed at the holder's election to a lower percentage at any time or to a higher percentage upon 61 days' notice to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.
F2: The warrant may be exercised on or after August 19, 2026, and on or prior to the earlier of (i) December 25, 2027 and (ii) thirty (30) days following the Issuer's public disclosure of the clearance of its Investigational New Drug Application by the U.S. Food and Drug Administration for CM5480; provided, however, that the holder will be prohibited, subject to certain exceptions, from exercising such warrant for shares of common stock of the Issuer to the extent that immediately prior to or after giving effect to such exercise, the holder, together with its affiliates and other attribution parties, would own more than 19.99% of the total number of shares of common stock of the Issuer then issued and outstanding, which percentage may be changed at the holder's election to a lower percentage at any time or to a higher percentage upon 61 days' notice to the Issuer.
F3: The warrant may be exercised on or after August 19, 2026 and on or prior to June 25, 2031; provided, however, that the holder will be prohibited, subject to certain exceptions, from exercising such warrant for shares of common stock of the Issuer to the extent that immediately prior to or after giving effect to such exercise, the holder, together with its affiliates and other attribution parties, would own more than 19.99% of the total number of shares of common stock of the Issuer then issued and outstanding, which percentage may be changed at the holder's election to a lower percentage at any time or to a higher percentage upon 61 days' notice to the Issuer.
VIVUS INC
Report date February 28, 2019 · Filed March 04, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,660 |
Reported balance
After 2019-02-28 transaction · row 1
1 source rowRow 1 · 2019-02-28 · Purchase · Acquired 8,500 · Balance 16,660 F1: This is the weighted average purchase price. Shares were purchased in multiple transactions at prices from $4.78 to $4.8998. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4. The amount reflected has been rounded to 4 decimal points. |
Filing footnotes · ownership attribution and instrument terms
F1: This is the weighted average purchase price. Shares were purchased in multiple transactions at prices from $4.78 to $4.8998. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4. The amount reflected has been rounded to 4 decimal points.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Invuity, Inc.
Report date October 23, 2018 · Filed October 23, 2018
Section 16 reporting ended · disclosed 2018-10-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2018-10-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-10-23 · Disposition to issuer · Disposed 163,795 · Balance 34,246 F1: Disposed of pursuant to that certain Agreement and Plan of Merger between the Issuer, Stryker Corporation and Accipiter Corp., dated as of September 10, 2018 (the "Merger Agreement"), in exchange for a cash payment of $7.40 per share, without interest, subject to any required withholding of taxes (the "Offer Price"). Row 2 · 2018-10-23 · Disposition to issuer · Disposed 34,246 · Balance 0 F2: These securities were restricted stock units ("RSUs"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. F3: The RSUs were cancelled pursuant to the Merger Agreement in exchange for an amount in cash per underlying share equal to the Offer Price. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.87 · Expires 2021-05-19 | Direct | 0 |
Reported balance
After 2018-10-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-10-23 · Disposition to issuer · Disposed 28,900 · Balance 0 F4: The option was cancelled pursuant to the Merger Agreement in exchange for an amount in cash equal to the product of (a) the excess of the Offer Price over the per-share exercise price of such option multiplied by (b) the number of unexercised shares subject to such option. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to that certain Agreement and Plan of Merger between the Issuer, Stryker Corporation and Accipiter Corp., dated as of September 10, 2018 (the "Merger Agreement"), in exchange for a cash payment of $7.40 per share, without interest, subject to any required withholding of taxes (the "Offer Price").
F2: These securities were restricted stock units ("RSUs"), each of which represented a contingent right to receive one share of the Issuer's Common Stock.
F3: The RSUs were cancelled pursuant to the Merger Agreement in exchange for an amount in cash per underlying share equal to the Offer Price.
F4: The option was cancelled pursuant to the Merger Agreement in exchange for an amount in cash equal to the product of (a) the excess of the Offer Price over the per-share exercise price of such option multiplied by (b) the number of unexercised shares subject to such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 19, 2026 Filed Aug 21, 2026 22:36 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantWarrant · Derivative | 186,729 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001576244-26-000005 · form4-08212026_100837.xml · derivative · entry 2 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 186,729 Underlying: Common Stock · 186,729 shares Expires 2031-06-25 F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. F3 · derivative.exercise_date: The warrant may be exercised on or after August 19, 2026 and on or prior to June 25, 2031; provided, however, that the holder will be prohibited, subject to certain exceptions, from exercising such warrant for shares of common stock of the Issuer to the extent that immediately prior to or after giving effect to such exercise, the holder, together with its affiliates and other attribution parties, would own more than 19.99% of the total number of shares of common stock of the Issuer then issued and outstanding, which percentage may be changed at the holder's election to a lower percentage at any time or to a higher percentage upon 61 days' notice to the Issuer. F3 · derivative.expiration_date: The warrant may be exercised on or after August 19, 2026 and on or prior to June 25, 2031; provided, however, that the holder will be prohibited, subject to certain exceptions, from exercising such warrant for shares of common stock of the Issuer to the extent that immediately prior to or after giving effect to such exercise, the holder, together with its affiliates and other attribution parties, would own more than 19.99% of the total number of shares of common stock of the Issuer then issued and outstanding, which percentage may be changed at the holder's election to a lower percentage at any time or to a higher percentage upon 61 days' notice to the Issuer. Read SEC document |
| August 19, 2026 Filed Aug 21, 2026 22:36 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantWarrant · Derivative | 186,729 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001576244-26-000005 · form4-08212026_100837.xml · derivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 186,729 Underlying: Common Stock · 186,729 shares Expires 2027-12-25 F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. F2 · derivative.exercise_date: The warrant may be exercised on or after August 19, 2026, and on or prior to the earlier of (i) December 25, 2027 and (ii) thirty (30) days following the Issuer's public disclosure of the clearance of its Investigational New Drug Application by the U.S. Food and Drug Administration for CM5480; provided, however, that the holder will be prohibited, subject to certain exceptions, from exercising such warrant for shares of common stock of the Issuer to the extent that immediately prior to or after giving effect to such exercise, the holder, together with its affiliates and other attribution parties, would own more than 19.99% of the total number of shares of common stock of the Issuer then issued and outstanding, which percentage may be changed at the holder's election to a lower percentage at any time or to a higher percentage upon 61 days' notice to the Issuer. F2 · derivative.expiration_date: The warrant may be exercised on or after August 19, 2026, and on or prior to the earlier of (i) December 25, 2027 and (ii) thirty (30) days following the Issuer's public disclosure of the clearance of its Investigational New Drug Application by the U.S. Food and Drug Administration for CM5480; provided, however, that the holder will be prohibited, subject to certain exceptions, from exercising such warrant for shares of common stock of the Issuer to the extent that immediately prior to or after giving effect to such exercise, the holder, together with its affiliates and other attribution parties, would own more than 19.99% of the total number of shares of common stock of the Issuer then issued and outstanding, which percentage may be changed at the holder's election to a lower percentage at any time or to a higher percentage upon 61 days' notice to the Issuer. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 12:45 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantCommon Stock | 186,729 | $0.80 | $149,999.41 |
DisclosureSEC source: 0001576244-26-000004 · form4-06292026_080603.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 366,435 F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. Read SEC document |
| September 18, 2025 Filed Sep 22, 2025 13:35 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 2,500 | $3.07 | $7,675.00 |
DisclosureSEC source: 0001576244-25-000007 · form4-09222025_090901.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By FMTC Custodian - Roth IRA FBO Eric W. Roberts Disclosed balance after: 84,150 Read SEC document |
| September 15, 2025 Filed Sep 17, 2025 13:45 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 3,400 | $2.68 | $9,104.86 |
DisclosureSEC source: 0001576244-25-000005 · form4-09172025_090902.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By FMTC Custodian - Roth IRA FBO Eric W. Roberts Disclosed balance after: 81,650 F1 · price: The weighted average purchase price for the transaction reported was $2.6779, and the range of prices were between $2.65 and $2.70. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| September 12, 2025 Filed Sep 15, 2025 16:31 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 5,000 | $3.12 | $15,600.00 |
DisclosureSEC source: 0001576244-25-000003 · form4-09152025_040948.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By FMTC Custodian - Roth IRA FBO Eric W. Roberts Disclosed balance after: 78,250 Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 16:00 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 2,343 | $3.15 | $7,377.64 |
DisclosureSEC source: 0001415889-25-024256 · form4-09112025_120901.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By FMTC Custodian - Roth IRA FBO Eric W. Roberts Disclosed balance after: 73,250 F1 · price: The weighted average purchase price for the transaction reported was $3.1488, and the range of prices were between $2.75 and $3.21. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| August 29, 2025 Filed Sep 2, 2025 17:05 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 800 | $2.74 | $2,192.00 |
DisclosureSEC source: 0001415889-25-023364 · form4-09022025_050918.xml · nonDerivative · entry 2 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By FMTC Custodian - Roth IRA FBO Eric W. Roberts Disclosed balance after: 70,907 Read SEC document |
| August 28, 2025 Filed Sep 2, 2025 17:05 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 9,200 | $2.86 | $26,339.60 |
DisclosureSEC source: 0001415889-25-023364 · form4-09022025_050918.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By FMTC Custodian - Roth IRA FBO Eric W. Roberts Disclosed balance after: 70,107 F1 · price: The weighted average purchase price for the transaction reported was $2.8630, and the range of prices were between $2.75 and $2.92. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| August 21, 2025 Filed Aug 25, 2025 13:30 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 3,508 | $2.79 | $9,797.14 |
DisclosureSEC source: 0001415889-25-022850 · form4-08252025_090801.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By FMTC Custodian - Roth IRA FBO Eric W. Roberts Disclosed balance after: 60,907 F1 · price: The weighted average purchase price for the transaction reported was $2.7928, and the range of prices were between $2.75 and $2.80. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| August 20, 2025 Filed Aug 21, 2025 16:00 UTC | CalciMedica, Inc. CALC · Entity 7804 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $1.53 Strike: $1.53 | $22,950.00 |
DisclosureSEC source: 0001415889-25-022550 · form4-08212025_120804.xml · derivative · entry 9 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,750 Underlying: Common Stock · 15,000 shares Expires 2035-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| August 20, 2025 Filed Aug 21, 2025 16:00 UTC | CalciMedica, Inc. CALC · Entity 7804 | Exercise / conversionCommon Stock | 15,000 | $1.53 | $22,950.00 |
DisclosureSEC source: 0001415889-25-022550 · form4-08212025_120804.xml · nonDerivative · entry 3 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,706 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 20, 2025 Filed Aug 21, 2025 16:00 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 2,000 | $2.72 | $5,440.00 |
DisclosureSEC source: 0001415889-25-022550 · form4-08212025_120804.xml · nonDerivative · entry 2 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By FMTC Custodian - Roth IRA FBO Eric W. Roberts Disclosed balance after: 57,399 Read SEC document |
| August 19, 2025 Filed Aug 21, 2025 16:00 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 1,000 | $2.79 | $2,790.00 |
DisclosureSEC source: 0001415889-25-022550 · form4-08212025_120804.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By FMTC Custodian - Roth IRA FBO Eric W. Roberts Disclosed balance after: 55,399 Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 17:45 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 5,076 | $2.90 | $14,708.73 |
DisclosureSEC source: 0001415889-25-022261 · form4-08192025_010801.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By FMTC Custodian - Roth IRA FBO Eric W. Roberts Disclosed balance after: 54,399 F1 · shares: The weighted average purchase price for the transaction reported was $2.8977, and the range of prices were between $2.80 and $2.90. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| July 22, 2025 Filed Jul 23, 2025 15:55 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 1,500 | $3.78 | $5,662.50 |
DisclosureSEC source: 0001415889-25-020164 · form4-07232025_030740.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By FMTC Custodian - Roth IRA FBO Eric W. Roberts Disclosed balance after: 49,323 Read SEC document |
| July 21, 2025 Filed Jul 22, 2025 16:15 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 1,500 | $3.37 | $5,055.00 |
DisclosureSEC source: 0001415889-25-020111 · form4-07222025_040709.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By FMTC Custodian - Roth IRA FBO Eric W. Roberts Disclosed balance after: 47,823 F1 · price: The weighted average purchase price for the transaction reported was $3.3707, and the range of prices were between $3.33 and $3.43. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| July 18, 2025 Filed Jul 18, 2025 18:36 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 2,000 | $2.88 | $5,760.00 |
DisclosureSEC source: 0001415889-25-019997 · form4-07182025_060757.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By FMTC Custodian - Roth IRA FBO Eric W. Roberts Disclosed balance after: 46,323 Read SEC document |
| July 14, 2025 Filed Jul 16, 2025 16:58 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 6,500 | $2.43 | $15,809.95 |
DisclosureSEC source: 0001415889-25-019822 · form4-07162025_040730.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By FMTC Custodian - Roth IRA FBO Eric W. Roberts Disclosed balance after: 44,323 F1 · price: The weighted average purchase price for the transaction reported was $2.4323, and the range of prices were between $2.30 and $2.55. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| July 09, 2025 Filed Jul 11, 2025 00:18 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 5,000 | $1.60 | $8,023.50 |
DisclosureSEC source: 0001415889-25-019655 · form4-07112025_120755.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By FMTC Custodian - Roth IRA FBO Eric W. Roberts Disclosed balance after: 37,823 Read SEC document |
| June 26, 2025 Filed Jun 27, 2025 23:35 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 4,500 | $1.44 | $6,482.70 |
DisclosureSEC source: 0001415889-25-018438 · form4-06272025_110619.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By FMTC Custodian - Roth IRA FBO Eric W. Roberts Disclosed balance after: 32,823 F1 · price: The weighted average purchase price for the transaction reported was $1.4406, and the range of prices were between $1.43 and $1.4499. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| June 24, 2025 Filed Jun 26, 2025 22:28 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (Right to Buy) · Derivative | 72,750 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001415889-25-018307 · form4-06262025_100613.xml · derivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,750 Underlying: Common Stock · 72,750 shares Expires 2035-04-22 F1 · date: The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 21:05 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 5,000 | $1.85 | $9,250.00 |
DisclosureSEC source: 0001415889-25-017250 · form4-06132025_050601.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By FMTC Custodian - Roth IRA FBO Eric W. Roberts Disclosed balance after: 28,323 Read SEC document |
| June 06, 2025 Filed Jun 9, 2025 20:08 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 5,000 | $1.78 | $8,875.00 |
DisclosureSEC source: 0001415889-25-016218 · form4-06092025_080603.xml · nonDerivative · entry 2 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By FMTC Custodian - Roth IRA FBO Eric W. Roberts Disclosed balance after: 23,323 F2 · price: The weighted average purchase price for the transaction reported was $1.755, and the range of prices were between $1.75 and $1.87. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:08 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 5,100 | $1.70 | $8,670.00 |
DisclosureSEC source: 0001415889-25-016218 · form4-06092025_080603.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By FMTC Custodian - Roth IRA FBO Eric W. Roberts Disclosed balance after: 18,323 F1 · price: The weighted average purchase price for the transaction reported was $1.70, and the range of prices were between $1.6638 an $1.7274. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| April 23, 2025 Filed Apr 25, 2025 20:32 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (Right to Buy) · Derivative | 160,000 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001415889-25-011360 · form4-04252025_080421.xml · derivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2035-04-22 F1 · derivative.exercise_date: Beginning March 26, 2025, 1/48th of the shares subject to the option vest in equal monthly installments over a four year period. Read SEC document |
| April 05, 2025 Filed Apr 8, 2026 01:50 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (Right to Buy) · Derivative | 83,358 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0001576244-26-000002 · form4-04072026_090407.xml · derivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,358 Underlying: Common Stock · 83,358 shares Expires 2036-04-04 F1 · derivative.exercise_date: Beginning April 1, 2026, 1/48th of the shares subject to the option vest in equal monthly installments over a four year period, provided, however, that no shares shall vest until the filing of the Company's registration statement on Form S-8 covering the shares of Common Stock that were automatically added to the shares authorized for issuance under the Company's 2023 Equity Incentive Plan on January 1, 2026 pursuant to an annual "evergreen" provision. Read SEC document |
| November 01, 2024 Filed Nov 1, 2024 17:24 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 53,333 | $3.75 | $199,998.75 |
DisclosureSEC source: 0001415889-24-025878 · form4-11012024_051115.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,706 Read SEC document |
| August 27, 2024 Filed Aug 28, 2024 23:10 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (Right to Buy) · Derivative | 77,500 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0001415889-24-022502 · form4-08282024_110858.xml · derivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,500 Underlying: Common Stock · 77,500 shares Expires 2034-08-26 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest in equal monthly installments over a four year period following March 28, 2024. Read SEC document |
| August 23, 2024 Filed Aug 26, 2024 22:00 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 3,000 | $3.57 | $10,710.00 |
DisclosureSEC source: 0001415889-24-022243 · form4-08262024_090856.xml · nonDerivative · entry 2 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By FMTC Custodian - Roth IRA FBO Eric W. Roberts Disclosed balance after: 13,223 Read SEC document |
| August 23, 2024 Filed Aug 26, 2024 22:00 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 2,000 | $3.58 | $7,157.00 |
DisclosureSEC source: 0001415889-24-022243 · form4-08262024_090856.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Oppenheimer & Co Inc. Custodian FBO Eric W Roberts Roth IRA Disclosed balance after: 46,894 Read SEC document |
| August 21, 2024 Filed Aug 22, 2024 22:02 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 5,000 | $4.04 | $20,200.00 |
DisclosureSEC source: 0001415889-24-022058 · form4-08222024_100832.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Oppenheimer & Co Inc. Custodian FBO Eric W Roberts Roth IRA Disclosed balance after: 44,894 Read SEC document |
| June 27, 2024 Filed Jun 28, 2024 22:52 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 5,000 | $3.22 | $16,100.00 |
DisclosureSEC source: 0001415889-24-018496 · form4-06282024_100627.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By FMTC Custodian - Roth IRA FBO Eric W. Roberts Disclosed balance after: 10,223 Read SEC document |
| April 02, 2024 Filed Apr 3, 2024 00:33 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 3,254 | $3.90 | $12,690.60 |
DisclosureSEC source: 0001415889-24-009884 · form4-04032024_120452.xml · nonDerivative · entry 2 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Oppenheimer & Co Inc. Custodian FBO Eric W Roberts Roth IRA Disclosed balance after: 39,894 Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 00:33 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 746 | $3.90 | $2,909.40 |
DisclosureSEC source: 0001415889-24-009884 · form4-04032024_120452.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Oppenheimer & Co Inc. Custodian FBO Eric W Roberts Roth IRA Disclosed balance after: 36,640 Read SEC document |
| March 28, 2024 Filed Apr 23, 2024 01:37 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (Right to Buy) · Derivative | 77,500 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0001415889-24-011346 · form4-04232024_010420.xml · derivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,500 Underlying: Common Stock · 77,500 shares Expires 2034-03-27 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest in equal monthly installments over a four year period following the date of grant. Read SEC document |
| February 05, 2024 Filed Feb 6, 2024 22:34 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantWarrant · Derivative | 45,543 | $0.13 Strike: $7.15 | $5,692.88 |
DisclosureSEC source: 0001415889-24-002832 · form4-02062024_100209.xml · derivative · entry 9 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,543 Underlying: Common Stock · 45,543 shares Expires 2026-12-31 F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of February 5, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. F4 · derivative.exercise_date: The warrant may be exercised on or after February 5, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter. F4 · derivative.expiration_date: The warrant may be exercised on or after February 5, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter. Read SEC document |
| February 05, 2024 Filed Feb 6, 2024 22:34 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantWarrant · Derivative | 45,543 | $0.13 Strike: $5.36 | $5,692.88 |
DisclosureSEC source: 0001415889-24-002832 · form4-02062024_100209.xml · derivative · entry 8 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,543 Underlying: Common Stock · 45,543 shares Expires 2024-12-31 F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of February 5, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. F3 · derivative.exercise_date: The warrant may be exercised on or after February 5, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter. F3 · derivative.expiration_date: The warrant may be exercised on or after February 5, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter. Read SEC document |
| February 05, 2024 Filed Feb 6, 2024 22:34 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantCommon Stock | 91,086 | $4.27 | $388,618.42 |
DisclosureSEC source: 0001415889-24-002832 · form4-02062024_100209.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,373 F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of February 5, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. Read SEC document |
| November 06, 2023 Filed Nov 9, 2023 01:41 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 2,400 | $3.12 | $7,488.00 |
DisclosureSEC source: 0001209191-23-054769 · doc4.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Oppenheimer & Co Inc. Custodian FBO Eric W Roberts Roth IRA Disclosed balance after: 35,894 Read SEC document |
| November 03, 2023 Filed Nov 6, 2023 23:40 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 5,860 | $2.70 | $15,827.86 |
DisclosureSEC source: 0001209191-23-054578 · doc4.xml · nonDerivative · entry 2 Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Oppenheimer & Co Inc. Custodian FBO Eric W Roberts Roth IRA Disclosed balance after: 22,245 F2 · price: The weighted average purchase price for the transaction reported was $2.701, and the range of prices were between $2.60 and $2.79496. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| November 03, 2023 Filed Nov 6, 2023 23:40 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 3,200 | $2.80 | $8,960.00 |
DisclosureSEC source: 0001209191-23-054578 · doc4.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,587 F1 · price: The weighted average purchase price for the transaction reported was $2.80, and the range of prices were between $2.795672 and $2.80. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| November 03, 2023 Filed Nov 8, 2023 01:42 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 11,249 | $2.83 | $31,845.92 |
DisclosureSEC source: 0001209191-23-054635 · doc4.xml · nonDerivative · entry 2 Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Oppenheimer & Co Inc. Custodian FBO Eric W Roberts Roth IRA Disclosed balance after: 33,494 F2 · price: The weighted average purchase price for the transaction reported was $2.831, and the range of prices were between $2.67 and $2.85. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| November 03, 2023 Filed Nov 8, 2023 01:42 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 3,700 | $2.77 | $10,249.00 |
DisclosureSEC source: 0001209191-23-054635 · doc4.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,287 F1 · price: The weighted average purchase price for the transaction reported was $2.77, and the range of prices were between $2.70 and $2.80. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| August 29, 2023 Filed Sep 5, 2023 22:07 UTC Amendment | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 223 | $3.02 | $673.46 |
DisclosureSEC source: 0001209191-23-048235 · doc4a.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By FMTC Custodian - Roth IRA FBO Eric W. Roberts Disclosed balance after: 5,223 Read SEC document |
| August 25, 2023 Filed Aug 29, 2023 23:34 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 736 | $3.18 | $2,340.48 |
DisclosureSEC source: 0001209191-23-047674 · doc4.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By FMTC Custodian - Roth IRA FBO Eric W. Roberts Disclosed balance after: 5,000 Read SEC document |
| August 22, 2023 Filed Aug 23, 2023 22:02 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 714 | $3.27 | $2,334.78 |
DisclosureSEC source: 0001209191-23-047106 · doc4.xml · nonDerivative · entry 2 Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By FMTC Custodian - Roth IRA FBO Eric W. Roberts Disclosed balance after: 4,264 F2 · price: The weighted average purchase price for the transaction reported was $3.27, and the range of prices were between $3.12 and $3.35. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| August 21, 2023 Filed Aug 23, 2023 22:02 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 1,750 | $3.25 | $5,687.50 |
DisclosureSEC source: 0001209191-23-047106 · doc4.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By FMTC Custodian - Roth IRA FBO Eric W. Roberts Disclosed balance after: 3,550 F1 · price: The weighted average purchase price for the transaction reported was $3.25, and the range of prices were between $3.20 and $3.30. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| June 26, 2023 Filed Jun 27, 2023 00:33 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 1,200 | $3.70 | $4,441.20 |
DisclosureSEC source: 0001209191-23-039831 · doc4.xml · nonDerivative · entry 3 Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,387 F1 · price: The weighted average purchase price for the transaction reported was $3.701, and the range of prices were between $3.53 and $3.7483. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| June 26, 2023 Filed Jun 27, 2023 00:33 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 200 | $3.53 | $706.00 |
DisclosureSEC source: 0001209191-23-039831 · doc4.xml · nonDerivative · entry 2 Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Oppenheimer & Co Inc. Custodian FBO Eric W Roberts Roth IRA Disclosed balance after: 16,385 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.